Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Moskowitz

Showing results (191-200 of 280) with videos related to

Pageof 28
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|September 17, 2013
A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remissionNeha Mehta, Jocelyn C Maragulia, Allison Moskowitz, et al.
Blood Advances|September 18, 2023
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphomaJulia Driessen, Gerben J C Zwezerijnen, Heiko Schöder, et al.
Archives of Insect Biochemistry and Physiology|June 17, 1998
Rapid purification and molecular modeling of AaIT peptides from venom of Androctonus australisY Nakagawa, M Sadilek, E Lehmberg, et al.
Leukemia & Lymphoma|June 11, 2014
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphomaTim Illidge, Reda Bouabdallah, Robert Chen, et al.
British Journal of Haematology|March 18, 2011
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centresStephen D Smith, Craig H Moskowitz, Robert Dean, et al.
Blood|September 26, 2000
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysisT Kewalramani, A D Zelenetz, E E Hedrick, et al.
Leukemia & Lymphoma|August 20, 2021
Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphomaJuan Pablo Alderuccio, Russ A Kuker, Priscila Barreto-Coelho, et al.
Blood|April 5, 2003
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphomaPaul A Hamlin, Andrew D Zelenetz, Tarun Kewalramani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab eraChristian Gisselbrecht, Bertram Glass, Nicolas Mounier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2009
Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantationTrudy N Small, Andrew D Zelenetz, Ariela Noy, et al.
Pageof 28

Showing results (191-200 of 280) with videos related to

Sort By:
Pageof 28
Clinical Lymphoma, Myeloma & Leukemia|September 17, 2013
A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remissionNeha Mehta, Jocelyn C Maragulia, Allison Moskowitz, et al.
Blood Advances|September 18, 2023
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphomaJulia Driessen, Gerben J C Zwezerijnen, Heiko Schöder, et al.
Archives of Insect Biochemistry and Physiology|June 17, 1998
Rapid purification and molecular modeling of AaIT peptides from venom of Androctonus australisY Nakagawa, M Sadilek, E Lehmberg, et al.
Leukemia & Lymphoma|June 11, 2014
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphomaTim Illidge, Reda Bouabdallah, Robert Chen, et al.
British Journal of Haematology|March 18, 2011
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centresStephen D Smith, Craig H Moskowitz, Robert Dean, et al.
Blood|September 26, 2000
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysisT Kewalramani, A D Zelenetz, E E Hedrick, et al.
Leukemia & Lymphoma|August 20, 2021
Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphomaJuan Pablo Alderuccio, Russ A Kuker, Priscila Barreto-Coelho, et al.
Blood|April 5, 2003
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphomaPaul A Hamlin, Andrew D Zelenetz, Tarun Kewalramani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab eraChristian Gisselbrecht, Bertram Glass, Nicolas Mounier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2009
Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantationTrudy N Small, Andrew D Zelenetz, Ariela Noy, et al.
Pageof 28